Liminal BioSciences Inc. has announced that it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. (“PBL”) to KKR & Co., a leading global investment firm (“KKR”).
Liminal BioSciences Inc. (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, has announced that it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. (“PBL”) to KKR & Co., a leading global investment firm (“KKR”).
Latham & Watkins LLP represents KKR & Co. in the transaction with a cross-border team led by London partner Kem Ihenacho and Silicon Valley partner Josh Dubofsky with London associates Terry Charalambous and Janine Leeder and Silicon Valley associate Alexander White and San Francisco associate Brianna Stellpflug. Advice was also provided on tech transactions and intellectual property matters by London partner Deborah Kirk with London associates Elva Cullen and Grace Erskine; on tax matters by London partner Karl Mah and San Francisco partner Kirt Switzer with London associate Aoife McCabe and San Francisco associate Jessica Chen; and on benefits and compensation matters by Los Angeles partner Michelle Carpenter.
